| Purity: | * |
|---|---|
| Model Number: | CAS: 317318-70-0 |
| Brand Name: | NJBN |
| Grade Standard: | |
| Type: | |
| Place of Origin: | China (Mainland) |
| MF: | C21H18F3NO3S2 |
| Other Names: | Cardarine |
| CAS No.: | 317318-70-0 |
Quick Details
Specifications
99% Highest Quality Sarms Powder CAS 317318-84-6 Gw-0742 / Gw610742
Quick Detail :
GW-501516
Alias : Cardarine
CAS : 317318-70-0
Assay : > 99%
MF : C21H18F3NO3S2
MW : 453.5
MP : 134-136°C
Appearance : White powder
Product Categories : Selective Androgen Receptor ; Intermediates & Fine Chemicals ; Pharmaceuticals ; Sulfur & Selenium Compounds ; kl ; Inhibitor
Usage : It had been investigated as a potential treatment for obesity , diabetes , dyslipidemia and cardiovascular disease . GW501516 could be used by athletes as an ergogenic performance enhancing drug .
Description :
GW501516 ( also known as GW-501 ,516 , GW1516 , GSK-516 and on the black market as Endurobol[1] ) is a PPARδ receptor agonist that was invented in a collaboration between Ligand Pharmaceuticals and GlaxoSmithKline in the 1990s , was entered into clinical development as a drug candidate for metabolic diseases and cardiovascular diseases , and was abandoned in 2007 because animal testing showed that the drug caused cancer to develop rapidly in several organs .
Quick Detail :
GW-501516
Alias : Cardarine
CAS : 317318-70-0
Assay : > 99%
MF : C21H18F3NO3S2
MW : 453.5
MP : 134-136°C
Appearance : White powder
Product Categories : Selective Androgen Receptor ; Intermediates & Fine Chemicals ; Pharmaceuticals ; Sulfur & Selenium Compounds ; kl ; Inhibitor
Usage : It had been investigated as a potential treatment for obesity , diabetes , dyslipidemia and cardiovascular disease . GW501516 could be used by athletes as an ergogenic performance enhancing drug .
Description :
GW501516 ( also known as GW-501 ,516 , GW1516 , GSK-516 and on the black market as Endurobol[1] ) is a PPARδ receptor agonist that was invented in a collaboration between Ligand Pharmaceuticals and GlaxoSmithKline in the 1990s , was entered into clinical development as a drug candidate for metabolic diseases and cardiovascular diseases , and was abandoned in 2007 because animal testing showed that the drug caused cancer to develop rapidly in several organs .
SARMs:
MK-2866 CAS:1202044-20-9, 841205-47-8
LGD-4033 CAS:1165910-22-4
GW-501516 CAS:317318-70-0
MK-677 CAS:159752-10-0
GTX-007/S4/Andarine CAS:401900-40-1
SR-9009 CAS:1379686-30-2
RAD-140 CAS:118237-47-0
YK-11 CAS:431579-34-9
AICAR CAS:2627-69-2
GW0742 CAS:317318-84-6
GS5816 CAS:1377049-84-7